ライフサイエンスコーパス: ledipasvir

1 evir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir.

2 rring resistance to NS5A inhibitors, such as ledipasvir.

3 sofosbuvir combined with the NS5A inhibitor ledipasvir.

4 S-9451) and after 12 weeks with sofosbuvir + ledipasvir.

5 treatment groups: 12 weeks of sofosbuvir and ledipasvir; 6 weeks of sofosbuvir, ledipasvir, and GS-96

6 b infection who received the combination of ledipasvir (90 mg) and sofosbuvir (400 mg) (ledipasvir/s

7 We gave patients 12 weeks of ledipasvir (90 mg) and sofosbuvir (400 mg) as a single c

8 reater were randomly assigned 1:1 to receive ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 or 24

9 reater were randomly assigned 1:1 to receive ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 or 24

10 sation sequence to receive 12 or 24 weeks of ledipasvir (90 mg) and sofosbuvir (400 mg) once daily (c

11 were prescribed a fixed-dose combination of ledipasvir (90 mg) and sofosbuvir (400 mg) once daily fo

12 re randomly assigned (1:1) to receive either ledipasvir (90 mg) and sofosbuvir (400 mg) or ledipasvir

13 fosbuvir (400 mg) and the HCV NS5A inhibitor ledipasvir (90 mg), with and without ribavirin--in patie

14 hat the fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to

15 All patients received ledipasvir, an NS5A inhibitor, and sofosbuvir, a nucleot

16 a fixed-dose combination tablet of 90 mg of ledipasvir and 400 mg of sofosbuvir orally once-daily fo

17 years received a combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 weeks

18 ven a fixed-dose combination tablet of 90 mg ledipasvir and 400 mg sofosbuvir orally once per day for

19 aily combination fixed-dose tablets of 90 mg ledipasvir and 400 mg sofosbuvir plus weight-based ribav

20 eeks of anti-HCV treatment using sofosbuvir, ledipasvir and a non-nucleoside polymerase-inhibitor (GS

21 went antiviral therapy (AVT) with sofosbuvir/ledipasvir and chemotherapy (14 rituximab plus cyclophos

22 single-tablet regimen of the NS5A inhibitor ledipasvir and NS5B nucleotide polymerase inhibitor sofo

23 ir for 12 weeks (group 4) or sofosbuvir plus ledipasvir and ribavirin for 12 weeks (group 5).

24 asvir for 8 weeks (group 1), sofosbuvir plus ledipasvir and ribavirin for 8 weeks (group 2), or sofos

25 usly demonstrated that adding a third DAA to ledipasvir and sofosbuvir (LDV/SOF) can result in high S

26 We assessed PROs in patients treated with ledipasvir and sofosbuvir (LDV/SOF) with and without RBV

27 ype 1 infection without cirrhosis to receive ledipasvir and sofosbuvir (ledipasvir-sofosbuvir) for 8

28 roups given fixed-dose combination tablet of ledipasvir and sofosbuvir (n = 25) or ledipasvir and sof

29 enotype 3 patients, 16 of 25 (64%) receiving ledipasvir and sofosbuvir alone achieved SVR12 compared

30 let of ledipasvir and sofosbuvir (n = 25) or ledipasvir and sofosbuvir along with ribavirin (n = 26).

31 r treatment (SVR12) with regimens containing ledipasvir and sofosbuvir and identify factors associate

32 mpared with all 26 patients (100%) receiving ledipasvir and sofosbuvir and ribavirin.

33 tients with HCV genotype 3 (n = 50) received ledipasvir and sofosbuvir and ribavirin.

34 Regimens containing ledipasvir and sofosbuvir are highly effective for a bro

35 One patient with HCV genotype 3 discontinued ledipasvir and sofosbuvir because of an adverse event (d

36 Thirteen patients (4%) discontinued the ledipasvir and sofosbuvir combination prematurely becaus

37 afety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this populatio

38 Ledipasvir and sofosbuvir for 12 weeks provided high rat

39 IV, administration of an oral combination of ledipasvir and sofosbuvir for 12 weeks was associated wi

40 lity of 12 weeks of combination therapy with ledipasvir and sofosbuvir for patients with chronic HCV

41 The combination of ledipasvir and sofosbuvir has been approved for treatmen

42 ents with HCV genotype 1, the combination of ledipasvir and sofosbuvir has been shown to cure high pr

43 domly assigned in a 1:1:1:1 ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination ta

44 The all-oral regimen of ledipasvir and sofosbuvir is an effective and safe treat

45 ants received a 3-drug regimen consisting of ledipasvir and sofosbuvir plus GS-9451 for 4 weeks, and

46 te the safety, tolerability, and efficacy of ledipasvir and sofosbuvir plus ribavirin in patients wit

47 enotype 3 infection who received 12 weeks of ledipasvir and sofosbuvir plus ribavirin, and by patient

48 with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sust

49 Ledipasvir and sofosbuvir treatment for 12 weeks was wel

50 f a fixed-dose combination tablet containing ledipasvir and sofosbuvir, once daily, plus ribavirin.

51 trial to evaluate the efficacy and safety of ledipasvir and sofosbuvir, with or without ribavirin, in

52 rrent guidelines do not recommend the use of ledipasvir and sofosbuvir, with or without ribavirin, in

53 ons (RASs) on response to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in

54 tients with HCV genotype 6 (n = 25) received ledipasvir and sofosbuvir.

55 ed with adults from phase 2 and 3 studies of ledipasvir and sofosbuvir.

56 tion of the hepatitis C virus NS5A inhibitor ledipasvir and the NS5B nucleotide polymerase inhibitor

57 combination therapy with the NS5A inhibitor ledipasvir and the NS5B polymerase inhibitor sofosbuvir

58 he efficacy and safety of the NS5A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofos

59 domly assigned to receive the NS5A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofos

60 [17%] of six patients receiving sofosbuvir, ledipasvir, and asunaprevir; one [17%] of six patients r

61 12 patients were assigned to sofosbuvir, ledipasvir, and asunaprevir; six to sofosbuvir, daclatas

62 o one of three treatment groups (sofosbuvir, ledipasvir, and asunaprevir; sofosbuvir, daclatasvir, an

63 notype 3a was less sensitive to daclatasvir, ledipasvir, and elbasvir, but equally sensitive to ombit

64 maximum concentration values for sofosbuvir, ledipasvir, and GS-331007 were within the predefined pha

65 GS-9669 for 6 weeks (n = 20), or sofosbuvir, ledipasvir, and GS-9451 for 6 weeks (n = 19).

66 of the 20 patients allocated to sofosbuvir, ledipasvir, and GS-9451 for 6 weeks (one patient was los

67 svir, and GS-9669; or 6 weeks of sofosbuvir, ledipasvir, and GS-9451.

68 edipasvir for 12 weeks (n = 20), sofosbuvir, ledipasvir, and GS-9669 for 6 weeks (n = 20), or sofosbu

69 of the 20 patients allocated to sofosbuvir, ledipasvir, and GS-9669 for 6 weeks (one patient relapse

70 buvir and ledipasvir; 6 weeks of sofosbuvir, ledipasvir, and GS-9669; or 6 weeks of sofosbuvir, ledip

71 luation of the concentrations of sofosbuvir, ledipasvir, and the sofosbuvir metabolite GS-331007.

72 paritaprevir/ritonavir/dasabuvir; sofosbuvir/ledipasvir; and daclatasvir/sofosbuvir, respectively, to

73 sofosbuvir+ribavirin; US$192 for sofosbuvir+ledipasvir; and US$115 for MK-8742+MK-5172.

74 Daclatasvir and ledipasvir belong to the NS5A inhibitor class, which dir

75 as associated with failure of daclatasvir or ledipasvir, but not ombitasvir.

76 the half-maximal effective concentration to ledipasvir by more than 100-fold reduced the rate of SVR

77 According to the label, sofosbuvir and ledipasvir can be prescribed for 8 weeks (SL8) in noncir

78 py with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor,

79 Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based ther

80 ing sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week,

81 Resistance to daclatasvir and ledipasvir differs from alisporivir, with mutations aris

82 aclatasvir, but no RASs were associated with ledipasvir failure, pointing to a limited efficacy of le

83 in for 8 weeks (group 2), or sofosbuvir plus ledipasvir for 12 weeks (group 3).

84 inhibitor regimen to receive sofosbuvir plus ledipasvir for 12 weeks (group 4) or sofosbuvir plus led

85 avirin for 24 weeks (n = 55), sofosbuvir and ledipasvir for 12 weeks (n = 20), sofosbuvir, ledipasvir

86 All 14 patients treated with sofosbuvir plus ledipasvir for 12 weeks achieved a sustained virologic r

87 4 weeks were re-treated with sofosbuvir plus ledipasvir for 12 weeks.

88 , 95% CI 83-100) allocated to sofosbuvir and ledipasvir for 12 weeks; in 19 (95%, 75-100) of the 20 p

89 nt-naive patients to receive sofosbuvir plus ledipasvir for 8 weeks (group 1), sofosbuvir plus ledipa

90 pid response were switched to sofosbuvir and ledipasvir for either 8 weeks or 12 weeks.

91 acokinetics led to the identification of 39 (ledipasvir, GS-5885).

92 ed SVR rates it was necessary to assume that ledipasvir, GS-9669 and GS-9451 rapidly reduce virus inf

93 RBV in 30, SOF + simeprevir in 11, and SOF + ledipasvir in 23.

94 vir/daclatasvir in 36.8%, and for sofosbuvir/ledipasvir in 40.2%.

95 r failure, pointing to a limited efficacy of ledipasvir in patients with genotype 3.

96 ed the efficacy and safety of sofosbuvir and ledipasvir in renal transplant patients with chronic HCV

97 valuated the effectiveness of sofosbuvir and ledipasvir in treatment-naive and treatment-experienced

98 and P7977-2025) and 5 studies of combination ledipasvir (LDV) and SOF (LDV/SOF; LONESTAR, ELECTRON [L

99 ve was to identify drug interactions between ledipasvir (LDV) and sofosbuvir (SOF) against a genotype

100 tudy, we assessed the efficacy and safety of ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks in HC

101 tor sofosbuvir (SOF) with the NS5A inhibitor ledipasvir (LDV) or the NS5B non-nucleoside inhibitor GS

102 nt, particularly the use of sofosbuvir (SOF)/ledipasvir (LDV) without RBV in this patient population.

103 f the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VD

104 l trial to assess the efficacy and safety of ledipasvir (LDV)-SOF plus RBV in patients with genotype

105 We evaluated the safety and efficacy of ledipasvir (LDV)-sofosbuvir (SOF) in treating HCV genoty

106 Ledipasvir (LDV)/sofosbuvir (SOF) has demonstrated high

107 ost commonly used regimen was sofosbuvir and ledipasvir (n = 21).

108 + RBV, n = 25; SOF + RBV, n = 36; and SOF + ledipasvir, n = 6) between January and November 2014.

109 of different concentrations of daclatasvir, ledipasvir, ombitasvir, elbasvir, ruzasvir, velpatasvir,

110 dy, direct-acting antiviral therapy with SOF/ledipasvir, ombitasvir/paritaprevir/ritonavir + dasabuvi

111 We compared using sofosbuvir/ledipasvir or ombitasvir/ritonavir/paritaprevir/dasabuvi

112 dasabuvir, or combinations of sofosbuvir and ledipasvir or sofosbuvir and velpatasvir had decreased e

113 ntly associated with failure of daclatasvir, ledipasvir, or ombitasvir in patients with genotype 1b i

114 ed interferon and ribavirin, sofosbuvir plus ledipasvir, or sofosbuvir plus ribavirin for 12 weeks ar

115 inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic

116 type) and were treated with sofosbuvir (SOF)/ledipasvir +/- ribavirin (85%) followed by SOF + daclata

117 irin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only).

118 For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-r

119 For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir

120 , for genotype 1 infections, sofosbuvir plus ledipasvir, sofosbuvir plus daclatasvir, or ombitasvir,

121 edipasvir (90 mg) and sofosbuvir (400 mg) or ledipasvir, sofosbuvir, and ribavirin (dosed according t

122 The combination of ledipasvir, sofosbuvir, and ribavirin for 12 weeks produ

123 We assessed the safety and efficacy of ledipasvir, sofosbuvir, and ribavirin in patients with H

124 d 25 received a 4-drug regimen consisting of ledipasvir, sofosbuvir, GS-9451, and GS-9669 for 4 weeks

125 e analyzed data from 1788 patients receiving ledipasvir-sofosbuvir (282 for 8 weeks, 910 for 12 weeks

126 All patients were treated with ledipasvir-sofosbuvir (90 mg and 400 mg) plus weight-bas

127 received a fixed-dose combination tablet of ledipasvir-sofosbuvir (90/400 mg) once daily for 12 week

128 nd 88 of 88 treatment experienced) receiving ledipasvir-sofosbuvir (95% CI 98-100) and 167 (98%) of 1

129 Across 11 phase 3 clinical trials of ledipasvir-sofosbuvir (SOF) and SOF, only 12 of 3004 pat

130 5%] of 170), and headache in those receiving ledipasvir-sofosbuvir and ribavirin (15 [8.8%] of 170).

131 Ledipasvir-sofosbuvir and ribavirin provided high rates

132 100) in the group that received 24 weeks of ledipasvir-sofosbuvir and ribavirin.

133 o 99) in the group that received 12 weeks of ledipasvir-sofosbuvir and ribavirin; 99% (95% CI, 95 to

134 coinfected kidney transplant recipients with ledipasvir-sofosbuvir at our 2 centers.

135 hronic HCV genotype 1 infection; the dose of ledipasvir-sofosbuvir currently used in adults was well

136 No patient who received 8 weeks of only ledipasvir-sofosbuvir discontinued treatment owing to ad

137 Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks was well-tolera

138 Conclusion: Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks was well-tolera

139 r treatment-naive and -experienced patients, ledipasvir-sofosbuvir for 12 weeks is highly effective f

140 ir-sofosbuvir plus ribavirin for 8 weeks, or ledipasvir-sofosbuvir for 12 weeks.

141 r-sofosbuvir plus ribavirin for 12 weeks and ledipasvir-sofosbuvir for 24 weeks provided similarly hi

142 svir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosb

143 svir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosb

144 s were achieved by 96% of patients receiving ledipasvir-sofosbuvir for 8 weeks (95% CI, 93%-98%), 97%

145 Ledipasvir-sofosbuvir for 8 weeks was associated with a

146 sessed the efficacy and safety of 6 weeks of ledipasvir-sofosbuvir for acute genotype 1 or 4 HCV in H

147 ate of cure with a fixed-dose combination of ledipasvir-sofosbuvir for patients with acute genotype 1

148 plus ribavirin group and 97% (91-100) in the ledipasvir-sofosbuvir group.

149 study to evaluate the efficacy and safety of ledipasvir-sofosbuvir in adolescents with chronic HCV ge

150 f the interferon- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney transplant recipients wi

151 f the interferon- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney transplant recipients wi

152 The oral regimen of ledipasvir-sofosbuvir is an effective and well-tolerated

153 Ledipasvir-sofosbuvir is effective at eradicating hepati

154 All patients received ledipasvir-sofosbuvir once daily for 6 weeks.

155 quentially assigned to either treatment with ledipasvir-sofosbuvir or ledipasvir-sofosbuvir plus riba

156 patient in either 12-week group discontinued ledipasvir-sofosbuvir owing to an adverse event.

157 plus weight-based ribavirin for 12 weeks, or ledipasvir-sofosbuvir plus placebo once daily for 24 wee

158 for a different duration) and 311 receiving ledipasvir-sofosbuvir plus ribavirin (212 for 12 weeks a

159 nd 87 of 87 treatment experienced) receiving ledipasvir-sofosbuvir plus ribavirin (95% CI 95-100).

160 d randomisation, 77 were assigned to receive ledipasvir-sofosbuvir plus ribavirin and 78 ledipasvir-s

161 Ledipasvir-sofosbuvir plus ribavirin for 12 weeks and le

162 combination tablet once daily for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledip

163 fixed-dose combination tablet for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledip

164 eeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks.

165 eeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks.

166 osbuvir (ledipasvir-sofosbuvir) for 8 weeks, ledipasvir-sofosbuvir plus ribavirin for 8 weeks, or led

167 were 96% (95% CI 89-99) for patients in the ledipasvir-sofosbuvir plus ribavirin group and 97% (91-1

168 Two (1.2%) of 170 patients in the ledipasvir-sofosbuvir plus ribavirin group discontinued

169 ther treatment with ledipasvir-sofosbuvir or ledipasvir-sofosbuvir plus ribavirin in a 1:1 ratio with

170 uvir, 93% (95% CI, 89 to 96) with 8 weeks of ledipasvir-sofosbuvir plus ribavirin, and 95% (95% CI, 9

171 100) in the group that received 24 weeks of ledipasvir-sofosbuvir plus ribavirin.

172 o 99) in the group that received 12 weeks of ledipasvir-sofosbuvir plus ribavirin; 98% (95% CI, 95 to

173 Seven patients (2%) discontinued ledipasvir-sofosbuvir prematurely due to adverse events.

174 ve patients with genotype 3 HCV, 12 weeks of ledipasvir-sofosbuvir provided a high level of SVR in th

175 sults indicated noninferiority of the 8-week ledipasvir-sofosbuvir regimen, on the basis of a noninfe

176 ty, and absence of drug-drug interactions of ledipasvir-sofosbuvir suggest that it could be an import

177 dosing required adjustment during and after ledipasvir-sofosbuvir therapy but antiretroviral regimen

178 Ledipasvir-sofosbuvir was highly effective at treating a

179 atment, a second cohort receiving 8 weeks of ledipasvir-sofosbuvir was to be enrolled.

180 Ledipasvir-sofosbuvir was well tolerated.

181 The single patient receiving 12 weeks of ledipasvir-sofosbuvir who did not reach SVR12 did not co

182 Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 o

183 e rate in the group that received 8 weeks of ledipasvir-sofosbuvir with ribavirin was 1 percentage po

184 rhosis to receive ledipasvir and sofosbuvir (ledipasvir-sofosbuvir) for 8 weeks, ledipasvir-sofosbuvi

185 nce interval [CI], 90 to 97) with 8 weeks of ledipasvir-sofosbuvir, 93% (95% CI, 89 to 96) with 8 wee

186 sponse in the group that received 8 weeks of ledipasvir-sofosbuvir, the rate in the 12-week group was

187 Patients received treatment with ledipasvir-sofosbuvir, which was provided on site, accor

188 gic response at 12 weeks after completion of ledipasvir-sofosbuvir.

189 ledipasvir-sofosbuvir plus ribavirin and 78 ledipasvir-sofosbuvir.

190 and 95% (95% CI, 92 to 98) with 12 weeks of ledipasvir-sofosbuvir.

191 l patients who received at least one dose of ledipasvir-sofosbuvir.

192 o 97) in the group that received 12 weeks of ledipasvir-sofosbuvir; 96% (95% CI, 91 to 99) in the gro

193 100) in the group that received 12 weeks of ledipasvir-sofosbuvir; 97% (95% CI, 94 to 99) in the gro

194 100) in the group that received 24 weeks of ledipasvir-sofosbuvir; and 99% (95% CI, 95 to 100) in th

195 o 99) in the group that received 24 weeks of ledipasvir-sofosbuvir; and 99% (95% CI, 97 to 100) in th

196 e (nine [5.3%] of 171) in patients receiving ledipasvir-sofosbuvir; and nasopharyngitis (40 [23.5%] o

197 Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in gen

198 The uptake of ledipasvir/sofosbuvir (LDV/SOF) regimens across health c

199 /ritonavir, ombitasvir, dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) regimens upon mortality.

200 the ION-4 study, black patients treated with ledipasvir/sofosbuvir (LDV/SOF) were significantly less

201 once-daily fixed-dose combination tablet of ledipasvir/sofosbuvir (LDV/SOF) with and without ribavir

202 SVR) for patients taking concomitant PPI and ledipasvir/sofosbuvir (LDV/SOF).

203 began treatment with sofosbuvir (n = 2986), ledipasvir/sofosbuvir (n = 11,327), or PrOD (n = 3174),

204 eved an SVR12 to 12 weeks (but not 24 weeks) ledipasvir/sofosbuvir (P < .001).

205 tudies evaluated a fixed-dose combination of ledipasvir/sofosbuvir +/- ribavirin administered for 8,

206 ed virologic response (SVR12), and safety of ledipasvir/sofosbuvir +/- ribavirin.

207 eeks after the end of treatment (SVR12) with ledipasvir/sofosbuvir and only a small effect in patient

208 infection (no significant difference between ledipasvir/sofosbuvir and PrOD regimens), 86.2% (95% CI,

209 e of SVR12 in treatment-naive patients given ledipasvir/sofosbuvir for 8 weeks (P = .011), but not fo

210 Approval of Ledipasvir/Sofosbuvir for the treatment of chronic hepat

211 y was to evaluate the safety and efficacy of ledipasvir/sofosbuvir in black patients using data from

212 se RASs had a small effect in patients given ledipasvir/sofosbuvir in combination with ribavirin for

213 An 8-week regimen of ledipasvir/sofosbuvir is effective for eligible patients

214 Short 8-week ledipasvir/sofosbuvir monotherapy regimens should perhap

215 ng genotype 1-infected patients treated with ledipasvir/sofosbuvir monotherapy, black patients had si

216 We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 h

217 enotype 3 infection (77.9% in patients given ledipasvir/sofosbuvir plus ribavirin, 87.0% in patients

218 Eight-week regimens of ledipasvir/sofosbuvir produced an SVR12 in 94.3% of elig

219 have minimal effects on patient responses to ledipasvir/sofosbuvir therapy.

220 A once-daily dosage of ledipasvir/sofosbuvir was similarly effective in black a

221 We examined the effectiveness of ledipasvir/sofosbuvir with or without ribavirin (LDV/SOF

222 afety and efficacy of 8, 12, and 24 weeks of ledipasvir/sofosbuvir with or without ribavirin for the

223 ledipasvir (90 mg) and sofosbuvir (400 mg) (ledipasvir/sofosbuvir) once daily, with or without ribav

224 is study was to model the impact of LDV/SOF (ledipasvir/sofosbuvir), the first Peg-IFN- and RBV-free

225 the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombita

226 taining sofosbuvir, simeprevir + sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritona

227 en all these drugs and sofosbuvir/ribavirin, ledipasvir/sofosbuvir, sofosbuvir/daclatasvir, sofosbuvi

228 d after receiving 12 weeks of treatment with ledipasvir/sofosbuvir.

229 e assessed treatment with the NS5A inhibitor ledipasvir, the nucleotide polymerase inhibitor sofosbuv

230 and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $1

231 he fixed-dose combination of sofosbuvir plus ledipasvir was efficacious in a small cohort of patients

232 Sofosbuvir-ledipasvir was the optimal strategy in most simulations

233 Sofosbuvir plus ledipasvir was well-tolerated with few adverse events.

234 Sofosbuvir and ledipasvir, which have recently been approved for treatm

235 Among patients treated with sofosbuvir and ledipasvir with or without GS-9669 or GS-9451, 100% (59/

236 Sofosbuvir and ledipasvir with ribavirin have high efficacy when taken

237 eated with the combination of sofosbuvir and ledipasvir without ribavirin for 8 or 12 weeks.

238 tion who received 12 weeks of sofosbuvir and ledipasvir without ribavirin.

239 rect-acting antiviral drug to sofosbuvir and ledipasvir would allow a shorter treatment duration.